WANBURY

BSE: 524212 29 Jul 2025

Healthcare

₹ 271

Wanbury Limited specializes in Pharmaceuticals within the Healthcare sector.

WANBURY

BSE: 524212 29 Jul 2025

Healthcare

₹ 271

Wanbury Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

18.1

Dividend Yield

0.0%

Debt to Equity

2.98

Stock P/E

26.3

Market Cap

802.0 Cr

WANBURY - Share Price & Details

Market Cap

₹802.0

High /Low

330.0 / 154.0

Stock P/E

26.3

Book Value

₹18.1

Dividend Yield

0.0

ROCE

34.9

ROE

₹70.0

Face Value

10.0

PEG Ratio

0.35

EVEBITDA

₹12.1

Debt

177

CMP / FCF

-95.7

Debt to equity

₹2.98

NP Ann

30.5

High price all time

330.0

Piotroski score

₹3.0

Graham Number

61.6

No. Eq. Shares

3.29

Net CF

₹0.66

Net profit

30.5

Price to book value

13.5

Interest Coverage

₹1.8

Low price all time

10.8

Industry PE

33.4

Reserves

₹26.5

Free Cash Flow

₹-22.5

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.46	91.0
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
WANBURY LTD.	1,738.44	202.57	1,720.00	5.98	802.0	26.3
KILITCH DRUGS (INDIA) LTD.	586.29	113.74	563.04	7.07	769	30.8
NGL FINE-CHEM LTD.	922.27	-5.21	930.18	-0.84	767	36.3

Peer Comparison Chart

About WANBURY

Wanbury Limited, with Security Code 524212, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Wanbury Limited (WANBURY) Announces Strategic Shift - Free Investment Community

(26 Jul 2025)

Wanbury Limited (WANBURY) Announces Strategic Shift ✌️【Trading Ideas】✌️ Our expert forecasting and real-time tracking system puts 200%+...

The five-year decline in earnings for Wanbury NSE:WANBURY) isn't encouraging, but shareholders are still up 722% over that period

(26 Jul 2025)

Wanbury Limited ( NSE:WANBURY ) shareholders have seen the share price descend 12% over the month. But that does not...

Wanbury Limited (524212) Signs Major Deal - Free Stock Market Mentorship

(26 Jul 2025)

Wanbury Limited (524212) Signs Major Deal ✌️【Equity Trends】✌️ Tired of following the crowd? Our analysts specialize in uncovering overlooked...

Wanbury Limited (524212) Announces Strategic Shift - Consistent double returns

(25 Jul 2025)

Wanbury Limited (524212) Announces Strategic Shift ✌️【Stock Observations】✌️ Access global financial data and expert market predictions for...

Is Wanbury Limited (524212) a Good Long Term Bet - Free Investment Portfolio Suggestions

(24 Jul 2025)

Is Wanbury Limited (524212) a Good Long Term Bet ✌️【Investor Trends】✌️ Access real-time market intelligence and exclusive stock alerts...

Wanbury Limited (524212) vs yyy - Tremendous gains

(24 Jul 2025)

Wanbury Limited (524212) vs yyy ✌️【Stock Analysis】✌️ From discovery to decision — we guide you toward stocks with the potential to double or...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	125.8	133.0	146.3	144.5	145.5	139.4	131.1	161.2	133.5	172.0
Expenses	119.3	118.8	132.9	127.1	124.4	121.2	120.1	141.2	119.5	142.3
Operating Profit	6.5	14.2	13.3	17.3	21.1	18.2	11.0	20.0	13.9	29.7
OPM %	5.13%	10.65%	9.12%	12.01%	14.53%	13.03%	8.37%	12.41%	10.45%	17.28%
Other Income	0.3	-2.7	0.6	0.8	0.7	0.9	0.9	1.6	0.8	1.8
Interest	6.6	7.5	5.8	7.7	8.3	7.5	7.6	10.1	10.2	9.0
Depreciation	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4
Profit before tax	-3.0	1.5	5.0	7.2	10.3	8.3	1.0	8.2	1.3	19.1
Tax %	7.6%	10.3%	-6.1%	2.4%	0.2%	-3.3%	0%	-1.8%	5.7%	6.3%
Net Profit	-3.3	1.0	4.7	7.4	10.3	8.1	1.0	8.0	1.2	20.3
EPS in Rs	-1	0.8	1.43	2.25	3.14	2.37	0.31	2.44	0.7	0

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	125.8	133.0	146.3	144.5	145.5	139.4	131.1	161.2	133.5	172.0
Expenses	119.3	118.8	132.9	127.1	124.4	121.2	120.1	141.2	119.5	142.3
Operating Profit	6.5	14.2	13.3	17.3	21.1	18.2	11.0	20.0	13.9	29.7
OPM %	5.13%	10.65%	9.12%	12.01%	14.53%	13.03%	8.37%	12.41%	10.45%	17.28%
Other Income	0.3	-2.7	0.6	0.8	0.7	0.9	0.9	1.6	0.8	1.8
Interest	6.6	7.5	5.8	7.7	8.3	7.5	7.6	10.1	10.2	9.0
Depreciation	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4
Profit before tax	-3.0	1.5	5.0	7.2	10.3	8.3	1.0	8.2	1.3	19.1
Tax %	7.6%	10.3%	-6.1%	2.4%	0.2%	0.8%	0%	1.8%	-5.7%	6.3%
Net Profit	-3.3	1.0	4.7	7.4	10.3	33.6	1.0	8.0	1.2	20.3
EPS in Rs	-1	0.8	1.43	2.25	3.13	12.45	0.31	2.34	0.7	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	5%
TTM:	4%

Compounded Profit Growth
10 Years:	25%
5 Years:	30%
3 Years:	78%
TTM:	2%

Stock Price CAGR
10 Years:	17%
5 Years:	74%
3 Years:	62%
1 Year:	95%

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	5%
TTM:	8%

Compounded Profit Growth
10 Years:	25%
5 Years:	30%
3 Years:	75%
TTM:	-8%

Stock Price CAGR
10 Years:	17%
5 Years:	74%
3 Years:	62%
1 Year:	95%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

WANBURY

WANBURY

WANBURY - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About WANBURY

Latest News

Wanbury Limited (WANBURY) Announces Strategic Shift - Free Investment Community

The five-year decline in earnings for Wanbury NSE:WANBURY) isn't encouraging, but shareholders are still up 722% over that period

Wanbury Limited (524212) Signs Major Deal - Free Stock Market Mentorship

Wanbury Limited (524212) Announces Strategic Shift - Consistent double returns

Is Wanbury Limited (524212) a Good Long Term Bet - Free Investment Portfolio Suggestions

Wanbury Limited (524212) vs yyy - Tremendous gains

Wanbury Limited (WANBURY) Announces Strategic Shift - Exceptional risk-adjusted gains

Wanbury Limited (524212) Hits 52 Week High - Rapid-fire capital growth

Wanbury Limited (524212) Signs Major Deal - High-octane financial growth

Technical Analysis: Wanbury Limited (524212) - Rapid-fire capital growth

Macro Trends and Their Impact on Wanbury Limited (WANBURY) - Rapid growth trajectories

Wanbury Limited (WANBURY) Announces Strategic Shift - Free Stock Selection

Wanbury Limited (524212) Signs Major Deal - Breakthrough financial growth

Wanbury Limited (WANBURY) Sees Unusual Trading Volume - Superior stock selection

Wanbury Limited (WANBURY) Sees Unusual Trading Volume - Powerful growth strategies

Technical Analysis: Wanbury Limited (524212) - Consistent triple-digit returns

Is Wanbury Limited (524212) a Good Long Term Bet - Breakout stock performance

Wanbury Limited (WANBURY) Signs Major Deal - Game-changing returns

Bullish Pattern Emerging on Wanbury Limited (524212) - Breakthrough stock performance

Wanbury Limited (WANBURY) Sees Unusual Trading Volume - Superior investment outcomes

Bullish Pattern Emerging on Wanbury Limited (524212) - Explosive earnings growth

Wanbury Limited (524212) Signs Major Deal - Unmatched profit growth

Wanbury Limited (WANBURY) Sees Unusual Trading Volume - Triple-digit returns

Wanbury Limited (WANBURY) Sees Unusual Trading Volume - Exceptional market positioning

Wanbury Limited (WANBURY) Announces Strategic Shift - Free Trading Psychology Coaching

Wanbury Limited (524212) Signs Major Deal - Unprecedented profit potential

Multibagger Share: 20 रुपयांच्या 'या' शेअरनं 5 वर्षात 1450 टक्के रिटर्न , गुंतवणूकदार मालामाल

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside

कोरोना काल से तेजी दिखा रहा 20 रुपये वाला यह शेयर, बारह महीने में 99.99% रिटर्न, 5 साल में 14 गुना हुआ पैसा

From Rs 18 to Rs 300: Ventura initiates coverage on this multibagger, see up to 52% upside

Has Wanbury declared dividend?

Subdued Growth No Barrier To Wanbury Limited (NSE:WANBURY) With Shares Advancing 26%

Wanbury's (NSE:WANBURY) Anemic Earnings Might Be Worse Than You Think

Wanbury Secures GMP Certification from Brazil Health Agency; Shares Slump 4%

Wanbury receives GMP certification from Brazil health regulator for its facility in Raigad, Maharashtra

Wanbury Secures ANVISA GMP Certification for Maharashtra Facility

Wanbury's Patalganga facility receives GMP certification from ANVISA

Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr

Zee Learn Ltd leads gainers in 'B' group

Pharma stock skyrockets 19% after reporting 1,570% QoQ increase in net profit

Wanbury's Tanuku facility granted GMP certificate by ANVISA

Wanbury Standalone March 2025 Net Sales at Rs 172.00 crore, up 23.38% Y-o-Y

Wanbury standalone net profit rises 150.74% in the March 2025 quarter

Rajani Associates advises Wanbury Ltd on ₹200 crore NCD issuance

Wanbury Limited to implement the SAP S/4 HANA Private Cloud Platform

Wanbury to implement the SAP S/4 HANA private cloud platform

Expert Chemicals Affirms No New Share Encumbrances for FY 2025

India’s pharma sector spared from US tariff hikes as Wanbury plans investor visit

Wanbury Limited's (NSE:WANBURY) Shares Bounce 31% But Its Business Still Trails The Market

Wanbury to launch new iron supplement C-RED & API Ketamine

Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE

Wanbury Limited Announces Financial Results and Capital Raising Initiatives

Pharma firm Wanbury refinances debt, cuts interest costs significantly

Wanbury Limited Strengthens Board with New Director Appointments

Wanbury refinances $150 cr debt, cuts interest costs significantly

Wanbury Faces Financial Struggles Amid Declining Sales and High Debt Concerns

Wanbury edges higher post conclusion of NCD refinancing at lower rates

Wanbury reports 88% drop in Q3 FY25 PAT

Benign Growth For Wanbury Limited (NSE:WANBURY) Underpins Stock's 28% Plummet

Wanbury Board approves fundraising and stock options grant; stocks down by 1%

ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility

Wanbury Limited's (NSE:WANBURY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Wanbury Experiences Revision in Its Stock Evaluation Amidst Strong Market Performance

We Believe Wanbury's (NSE:WANBURY) Earnings Are A Poor Guide For Its Profitability

Wanbury Standalone September 2024 Net Sales at Rs 161.19 crore, up 11.58% Y-o-Y

Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

Is Wanbury (NSE:WANBURY) Using Too Much Debt?

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

Akums Drugs & Pharmaceuticals promotes Jitendra Mishra as Senior Vice President

Wanbury Limited (NSE:WANBURY) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Wanbury Shares Hit 5% Upper Circuit on API Pipeline and Launches